Kim Eunha, Yang Katherine S, Kohler Rainer H, Dubach John M, Mikula Hannes, Weissleder Ralph
†Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, Massachusetts 02114, United States.
‡Department of Systems Biology, Harvard Medical School, 200 Longwood Avenue, Boston, Massachusetts 02115, United States.
Bioconjug Chem. 2015 Aug 19;26(8):1513-8. doi: 10.1021/acs.bioconjchem.5b00152. Epub 2015 Jun 9.
Bruton's tyrosine kinase (Btk) is intricately involved in anti-apoptotic signaling pathways in cancer and in regulating innate immune response. A number of Btk inhibitors are in development for use in treating B-cell malignancies and certain immunologic diseases. To develop robust companion imaging diagnostics for in vivo use, we set out to explore the effects of red wavelength fluorochrome modifications of two highly potent irreversible Btk inhibitors, Ibrutinib and AVL-292. Surprisingly, we found that subtle chemical differences in the fluorochrome had considerable effects on target localization. Based on iterative designs, we developed a single optimized version with superb in vivo imaging characteristics enabling single cell Btk imaging in vivo. This agent (Ibrutinib-SiR-COOH) is expected to be a valuable chemical tool in deciphering Btk biology in cancer and host cells in vivo.
布鲁顿酪氨酸激酶(Btk)复杂地参与癌症中的抗凋亡信号通路以及调节先天性免疫反应。多种Btk抑制剂正在研发中,用于治疗B细胞恶性肿瘤和某些免疫疾病。为了开发用于体内的强大的伴随成像诊断方法,我们着手探索两种高效不可逆Btk抑制剂依鲁替尼和AVL-292的红色波长荧光染料修饰的效果。令人惊讶的是,我们发现荧光染料中细微的化学差异对靶点定位有相当大的影响。基于迭代设计,我们开发出了一个具有出色体内成像特性的单一优化版本,能够在体内对单细胞Btk进行成像。这种试剂(依鲁替尼-硅罗丹明-COOH)有望成为一种有价值的化学工具,用于在体内解读癌症和宿主细胞中的Btk生物学特性。